Analysts forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will announce ($1.81) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Alnylam Pharmaceuticals’ earnings, with estimates ranging from ($2.28) to ($1.58). Alnylam Pharmaceuticals reported earnings of ($1.61) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 12.4%. The firm is scheduled to announce its next earnings results on Thursday, August 1st.
On average, analysts expect that Alnylam Pharmaceuticals will report full year earnings of ($7.41) per share for the current year, with EPS estimates ranging from ($8.42) to ($6.62). For the next fiscal year, analysts anticipate that the company will report earnings of ($6.90) per share, with EPS estimates ranging from ($9.16) to ($4.90). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.20) by $0.47. Alnylam Pharmaceuticals had a negative return on equity of 55.33% and a negative net margin of 929.51%. The firm had revenue of $33.29 million for the quarter, compared to analysts’ expectations of $21.60 million. During the same period in the previous year, the firm earned ($1.22) earnings per share. The business’s revenue was up 52.0% compared to the same quarter last year.
In other Alnylam Pharmaceuticals news, Director Philip A. Sharp sold 15,000 shares of the business’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $88.23, for a total value of $1,323,450.00. Following the sale, the director now directly owns 250,633 shares of the company’s stock, valued at $22,113,349.59. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.60% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Meeder Asset Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 332.9% in the first quarter. Meeder Asset Management Inc. now owns 342 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 263 shares in the last quarter. US Bancorp DE boosted its holdings in Alnylam Pharmaceuticals by 66.2% in the first quarter. US Bancorp DE now owns 369 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 147 shares in the last quarter. Flagship Harbor Advisors LLC bought a new stake in Alnylam Pharmaceuticals in the first quarter worth $47,000. Quadrant Capital Group LLC boosted its holdings in Alnylam Pharmaceuticals by 543.2% in the first quarter. Quadrant Capital Group LLC now owns 521 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 440 shares in the last quarter. Finally, FUKOKU MUTUAL LIFE INSURANCE Co boosted its holdings in Alnylam Pharmaceuticals by 40.0% in the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 700 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 200 shares in the last quarter. 87.89% of the stock is currently owned by institutional investors and hedge funds.
ALNY opened at $68.73 on Tuesday. The company has a current ratio of 9.33, a quick ratio of 9.12 and a debt-to-equity ratio of 0.20. Alnylam Pharmaceuticals has a 52-week low of $60.27 and a 52-week high of $124.21.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
See Also: Trading based on a resistance level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.